English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219703
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine

AuthorsMartín-Moreno, Alba; Jiménez Blanco, José L.; Mosher, Jamie; Swanson, Douglas R.; García-Fernández, José M.; Sharma, A.; Ceña, Valentín; Muñoz-Fernandez, M. Angeles
Polycationic nanoparticles
Fluorescence peptides
Issue Date2020
PublisherMultidisciplinary Digital Publishing Institute
CitationPharmaceutics 12: 656 (2020)
AbstractFinding a functional cure for HIV-1 infection will markedly decrease the social and economic burden of this disease. In this work, we have taken advantage of the antigen presenting cell role of human dendritic cells (DCs) to try to induce an immune response to HIV-derived peptide delivered to DCs using two different polycationic nanoparticles: a G4 PAMAM dendrimer modified to a 70/30 ratio of hydroxyl groups/amines and a cyclodextrin derivative. We have studied peptide delivery using a fluorescence peptide and have studied the immune response generation by cytokine determination and flow cytometry. We have found a robust delivery of the antigenic peptide to DCs and activated dendritic cell-mediated peripheral blood mononuclear cells (PBMCs) proliferation using the mixed lymphocyte reaction. However, no expression of markers indicating activation of either B or T lymphocytes was observed. Moreover, the release of the pro-inflammatory cytokine TNF-¿ or IL-2 was only observed when DCs treated with either the dendrimer or the dendriplex containing the peptide. Antigenic peptide delivery to DCs is a promising approach to generate a vaccine against HIV-1 infection. However, more studies, including the simultaneous delivery of several antigenic peptides from different viral proteins, can markedly improve the immune response. View Full-Text
Publisher version (URL)http://dx.doi.org/10.3390/pharmaceutics12070656
Identifiersdoi: 10.3390/pharmaceutics12070656
issn: 1999-4923
Appears in Collections:(IIQ) Artículos
Files in This Item:
File Description SizeFormat 
808367.pdf2,95 MBUnknownView/Open
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.